Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice.
Prophylactic treatment with human granulocyte colony-stimulating factor (hG-CSF) affords significant protection against systemic aspergillosis or pulmonary aspergillosis in neutropenic (cyclophosphamide-treated) mice but not in cortisone-treated animals. Cryptococcosis does not respond to hG-CSF therapy. Our data show that granulocytes play an important role in the immune defense against aspergillosis, but not against cryptococcosis. Combined treatment using hG-CSF and conventional antimycotics shows a significant beneficial effect in systemic or pulmonary aspergillosis.
Polak-Wyss
A
A
F. Hoffmann-La Roche Ltd, Basle, Switzerland.
D000818:Animals; D001228:Aspergillosis / Q000517:prevention & control*; D001232:Aspergillus fumigatus; D003453:Cryptococcosis / Q000517:prevention & control*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy; D008172:Lung Diseases, Fungal / Q000517:prevention & control*; D051379:Mice; D009503:Neutropenia / Q000150:complications
D016179:Granulocyte Colony-Stimulating Factor